Specjalistyczna Przychodnia Lekarska Alergo Med Sp. z o.o.

Poznan 27 trials 5 recruiting

27 Registered trials

5 Currently recruiting

Organisation

Specjalistyczna Przychodnia Lekarska Alergo Med Sp. z o.o.

Location

Poznan, Poland

Identifier

ORG-100044264

Address

Ul Mieczyslawa Niedzialkowskiego 10a/50, 61-578, Poland

Departments

#5753: Allergology
2653: Dermatologia
5204: Pulmonology
9502
Alergologia
Allergology
N/A
NA
not applicable
Specjalistyczna Przychodnia Lekarska Alergo Med Sp. z o.o
Specjalistyczna Przychodnia Lekarska Alergo Med Sp. z o.o.

Clinical trials at this site (27)

Search interface

An Open-Label Extension to Study the Long-Term Effect of Dexpramipexole in Participants with Severe Eosinophilic Asthma (EXHALE-5) Under evaluation

2024-510810-33-00 Severe eosinophilic asthma 5 2024-10-14
"A Clinical Study to Evaluate the Effectiveness of Beltavac® with polymerized extract of grass pollen mixture in allergic rhinoconjunctivit… Not authorised

2023-510033-28-00 allergic rhinoconjunctivitis caused due to exposure to 4
"A Clinical Study to Evaluate the Effectiveness of Beltavac® with polymerized extract of grass pollen mixture in allergic rhinoconjunctivit… Not authorised

2025-520581-22-00 Allergic rhinoconjunctivitis caused due to exposure to 4
Randomised efficacy and safety clinical trial of PQ Birch in subjects with seasonal allergic rhinitis and/or rhinoconjunctivitis induced by … Pending

2023-507427-28-00 seasonal allergic rhinitis and/or rhinoconjunctivitis 5
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants with Moderate-to-Severe Atopic Dermatitis (ADAPTIVE) Pending

2024-520117-50-00 Atopic Dermatitis 4
A clinical trial to provide continued access to remibrutinib (LOU064) for people who are benefiting from it in a previous remibrutinib trial Pending

2025-524078-40-00 Chronic Spontaneous Urticaria 5
Therapeutic equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in subjects with mild to moderate asthma (TRECONY) Recruiting

2025-521456-35-00 Mild to moderate asthma 4 2026-04-13
A Study to Evaluate Brenipatide Compared with Placebo in Adult Participants with Uncontrolled Moderate to Severe Asthma Recruiting

2025-522640-41-00 Asthma 4 2026-02-13
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-to-Severe Asthma Recruiting

2024-517866-40-00 Moderate-to-severe Asthma 4 2025-09-29
A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis Recruiting

2023-508817-18-00 Perennial Allergic Rhinitis (PAR) 5 2024-10-08
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered-Dose Inhaler on Cardiopulmonary Outcomes in C… Recruiting

2023-507407-59-00 Chronic Obstructive Pulmonary Disease (COPD) 5 2024-07-04
Study to assess whether Verekitug can improve the control of Chronic Obstructive Pulmonary Disease (COPD) Ended

2025-520488-42-00 Moderate-to-Severe Chronic Obstructive Pulmonary Diseas 4 2025-09-17
52 weeks double-blind, double-dummy, randomized placebo-controlled trial to evaluate safety, efficacy and tolerability of remibrutinib in co… Ended

2022-502161-19-00 Chronic Spontaneous Urticaria 5 2024-03-12
An extension study of long-term efficacy, safety and tolerability of remibrutinib in chronic spontaneous urticaria patients who completed pr… Ended

2024-510818-33-00 Chronic Spontaneous Urticaria 5 2023-01-24
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy of PURETHAL Mites Mixture 50,000 AUeq/mL Subcutane… Ended

2023-504942-75-01 Moderate to Severe Allergic Rhinitis/Rhinoconjunctiviti 5 2024-08-22
This is a clinical trial (study), to be conducted at multiple clinical sites, of an oral study drug (EP262) that will be investigated in adu… Ended

2023-504799-94-00 Chronic Spontaneous Urticaria 4 2024-02-20
A Phase 2 study to evaluate the efficacy and safety of RPT193 in adults with moderate-to-severe T2-high asthma who are partially controlled … Ended

2022-502854-16-00 Asthma 4 2023-11-26
Efficacy and safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund maintenance therapy Ended

2022-502208-64-00 Asthma 4 2023-11-25
This is a study to evaluate dose-flexibility of Upadacitinib in Adult Subjects with Moderate to Severe Atopic Dermatitis Ended

2023-504869-23-00 Dermatitis atopic 11 2023-05-31
A 52-week Clinical Trial to Study the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-2) Ended

2023-507665-25-00 Severe Eosinophilic asthma 5 2023-04-25
A 24-week Clinical Trial to Study the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma (EXHALE-4) Ended

2023-509739-22-00 Eosinophilic asthma 5 2023-04-25
Long-term Efficacy and Safety of Tozorakimab in Participants with Chronic Obstructive Pulmonary Disease with a History of Exacerbations. Ended

2022-501063-41-00 Chronic Obstructive Pulmonary Disease (COPD) 5 2023-04-20
Tezepelumab Efficacy and Safety in Reducing Oral Corticosteroid Use in Adults with Oral Corticosteroid Dependent Asthma Ended

2023-504648-33-00 Oral Corticosteroid Dependent Asthma 5 2022-07-19
The efficacy and safety of two doses of CHF6001 DPI as add-on to maintenance COPD triple therapy Ended

2023-510174-13-00 Chronic Obstructive Pulmonary Disease (COPD) 5 2021-06-17